MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples

[1]  Xiao Li,et al.  MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples , 2013, BMC Cancer.

[2]  W. Guo,et al.  MicroRNA‐9 up‐regulates E‐cadherin through inhibition of NF‐κB1–Snail1 pathway in melanoma , 2012, The Journal of pathology.

[3]  E. Berns,et al.  MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.

[4]  S. Rosenwald,et al.  Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. , 2009, Gynecologic oncology.

[5]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[6]  Bo Liu,et al.  Down-regulated miR-9 and miR-433 in human gastric carcinoma , 2009, Journal of experimental & clinical cancer research : CR.

[7]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[8]  A. Addario,et al.  Role of microRNAs in drug-resistant ovarian cancer cells. , 2008, Gynecologic oncology.

[9]  Stephen P Finn,et al.  Potential role of miR-9 and miR-223 in recurrent ovarian cancer , 2008, Molecular Cancer.

[10]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[11]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[12]  Asli Silahtaroglu,et al.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.

[13]  J. Baeten,et al.  High‐throughput microRNAome analysis in human germ cell tumours , 2007, The Journal of pathology.

[14]  Kazuhiko Hayashi,et al.  Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. , 2007, RNA.

[15]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[16]  Georgia Salanti,et al.  Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. , 2006, Journal of the National Cancer Institute.

[17]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[18]  Ranit Aharonov,et al.  MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. , 2004, Genome research.

[19]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[20]  Nan Li,et al.  Rab39, a novel Golgi-associated Rab GTPase from human dendritic cells involved in cellular endocytosis. , 2003, Biochemical and biophysical research communications.

[21]  D. Ginzinger,et al.  Effect of Duration of Fixation on Quantitative Reverse Transcription Polymerase Chain Reaction Analyses , 2002, Modern Pathology.

[22]  H. Reesink,et al.  The duration of fixation influences the yield of HCV cDNA-PCR products from formalin-fixed, paraffin-embedded liver tissue. , 1994, Journal of virological methods.

[23]  E. Berns,et al.  Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. , 2010, The international journal of biochemistry & cell biology.

[24]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. , 2003, Lancet.